INTRODUCTION :Des anomalies de la circulation pulmonaire prédisposant au développement de l’hypertension pulmonaire ont été reconnues dans l’hypertension systémique. Une hyperleptinémie a été décrite comme impliquée dans la pathogénie de l’hypertension systémique et de l’hypertension artérielle pulmonaire. Cependant, les effets de la leptine sur la vasoréactivité pulmonaire restent méconnus. OBJECTIFS :Dans ce contexte, le présent travail consistait à évaluer ex vivo les effets vasomoteurs de la leptine en comparant (1) les circulations artérielles systémique et pulmonaire, (2) en présence ou non de l’endothélium, (3) chez des rats spontanément hypertendus (SHR ;un modèle génétique d’hypertension systémique) versus normotensifs. METHODES :La vasoréactivité à la phényléphrine, endothéline-1 (ET-1) et leptine a été étudiée sur des artères pulmonaires et aortes thoraciques de rats SHR et Wistar avec et sans endothélium. De l’imagerie calcique a été réalisée sur des cultures primaires de cellules musculaires lisses vasculaires traitées à la leptine. Ces résultats ont été interprétés à la lumière de la pathobiologie des vaisseaux. RESULTATS :Chez les rats Wistar, la leptine induisait la vasodilatation des artères pulmonaires et aortes thoraciques pré-contractées par la phényléphrine ou l’ET-1. Cette vasodilatation était endothélio-dépendante. Chez les SHR, cette vasodilatation endothélio-dépendante était altérée dans les artères pulmonaires. Dans les deux souches de rats la réponse à la leptine était plus importante dans les aortes que dans les artères pulmonaires. Chez les SHR, les artères pulmonaires présentaient une hypertrophie de la média, associée à une surexpression génique d’ET-1 et des récepteurs à l’ET-1: ETA et ETB. Dans les artères de SHR sans endothélium, la leptine induisait une vasoconstriction, dépendante du calcium extracellulaire et des stocks calciques intracellulaires. En effet, la leptine induisait une augmentation des concentrations intracellulaires en calcium dans les cellules musculaires lisses isolées à partir d’artère pulmonaire et d’aorte thoracique, et ce de manière plus importante chez les SHR. Les artères de SHR présentaient une expression génique accrue du canal cationique TRPC6. CONCLUSION :La perte de la vasodilatation endothelio-dépendante induite par la leptine, dans un contexte d’augmentation d’ET-1, et de supplément de calcium dans les cellules musculaires lisses, pourrait contribuer à l’augmentation de la résistance vasculaire pulmonaire observée dans l’hypertension systémique. / Doctorat en Sciences biomédicales et pharmaceutiques (Médecine) / info:eu-repo/semantics/nonPublished

Cardiovascular diseases account for the majority of deaths both worldwide and in the Czech Republic. Main factors contributing heart disease development, aside age and sex, are obesity, high blood pressure and high blood cholesterol and triglyceride levels. Spontaneously hypertensive rat (SHR) was developed and used for search of genetic determinants of these traits. This commonly used rat model develops hypertension, dyslipidemia, and insulin resistance naturally which is caused by aberrant Cd36 fatty acid translocase gene. Previous studies have shown that rescue of Cd36 performed in the transgenic SHR-Tg19 strain enhances cardiac beta-adrenergic system, slightly increases heart mass and leads to higher susceptibility to arrhythmias. The present thesis had two main aims: 1) To investigate whether and how a transgenic rescue of Cd36 in SHR affects protein composition, mitochondrial function and activity of selected metabolic enzymes of the heart. 2) To study the expression and distribution of selected components of beta-adrenergic signaling system in lipid raft isolated form membranes using the TX-100 detergent. We set to compare two commonly used proteomic approaches, 2D electrophoresis with MALDI-TOF mass spectrometry and label-free LC-MS. The results did not reveal any overlap between...

Intravenous injection of substance P (SP) increases blood pressure in normotensive rats by stimulating sympathetic ganglia. This study compared the effects of SP to increase renal nerve firing and blood pressure in normotensive and hypertensive rats treated with chlorisondamine. The increase in renal nerve firing was greatest in spontaneously hypertensive rats (SHR), intermediate in Wistar rats, and least in Wistar-Kyoto (WKY) rats. Blood pressure was increased more in SHR than in Wistar rats. Blood pressure was not increased in WKY rats. Responses to the ganglionic stimulant 1, 1-dimethyl-4-phenylpiperazinium were the same in the three strains. These results suggest that there is a selective increase in the action of SP on sympathetic ganglia of SHR and that ganglion responsiveness to SP is correlated with its effect on blood pressure.

No description available.

Intravenous injection of substance P (SP) stimulates sympathetic ganglia to evoke a greater increase in renal sympathetic nerve activity, heart rate (HR) and blood pressure (BP) in hypertensive than normotensive rats due to upregulation of the NK1 receptor. These experiments were designed to determine the cellular basis for the enhanced ganglionic responsiveness to NK1 agonists in spontaneously hypertensive rats (SHR) in comparison to their normotensive counterparts, Wistar-Kyoto rats (WKY). Studies were also conducted to determine whether the increased ganglion responsiveness to SP in SHR is causally related to the increased BP or is a unique characteristic of this model of essential hypertension. Nerve recordings were made from the external carotid branch of the superior cervical ganglion (SCG) in pentobarbital anesthetized rats. Animals were treated with the ganglion blocking agent chlorisondamine (10.5 μmol/kg) and pre- and postganglionic SCG nerves were cut. SP (1.0 to 100 nmol/kg) evoked a greater increase in postganglionic nerve firing from the SCG of SHR vs. WKY. Intracellular microelectrode recordings were made from isolated SCG. Membrane properties were similar between strains. Picospritzer application of the NK1 agonist GR-73632 (100 μM, 1 s) caused slow depolarization and increased neuron excitability. Depolarization amplitude and duration were similar between strains, however, a greater percentage of neurons were depolarized by the NK1 agonist in SHR. To determine if the ganglion sensitivity to SP was correlated with blood pressure WKY were made hypertensive by unilateral nephrectomy and deoxycorticosterone acetate (DOCA)/salt treatment. Tail cuff BP was the same in treated WKY and untreated SHR. Increases in sympathetic nerve activity, HR and BP in response to SP (1.0 to 100 nmol/kg) were the same in treated and untreated WKY rats. In conclusion, SHR are more responsive to ganglion stimulation by NK1 agonists due to a greater number of responsive cells within their SCG rather than an enhanced responsiveness of individual neurons. The increased sympathetic nerve responsiveness to SP is an inherent characteristic and not an adaptive response of sympathetic ganglion neurons to hypertension. This enhanced action of SP at sympathetic ganglia may contribute to the elevated sympathetic outflow observed in this model of hypertension.

For optimal growth, plants have evolved strategies to integrate environmental signals to coordinate complex developmental and defensive processes to cope with the changing surroundings. Under challenges, plants prioritize their defense over growth. This trade-off involves complex interactions between multiple hormonal pathways and developmental networks. We discovered that JACKDAW (JKD), the core component of the SHORTROOT (SHR)-SCARECROW (SCR)- JKD plant developmental regulatory network is linking defense responses to the developmental programming. Unlike the well-studied function of JKD in root development, its function in leaves is yet to be understood. We found that JKD is expressed on the abaxial side of the leaf ground tissue. It has conserved functions in promoting SHR nuclear retention and restricting cyclinD6 expression in the leaf. Additionally, JKD has a function in leaf internal architecture establishment, including suppression of the bundle sheath cell division and shaping of the leaf ground tissue. We also found that SHR is a universal asymmetric cell division (ACD) activator, as ectopic SHR expression in the leaf ground tissue promotes stomata development via promoting the ACD to produce more stomata precursor cells. We showed that the knockout mutant of JKD has larger rosettes and better photosynthesis capacity, while the basal defense level and resistance to Botrytis cinerea, a necrotrophic pathogen, are enhanced. Our transcriptome and transcription studies revealed that JKD suppresses the expression of the plant defense hormone Jasmonic acid (JA) response genes and is itself downregulated by JA. This suggests that JKD is involved in the JA signaling, which mediates defense responses for wounding and herbivore attacks. Together, our study indicates that the loss of JKD uncoupled the plant growth-defense trade-off. JKD is a new link between plant development and defense. To verify whether this function of JKD is conserved in crops, JKD orthologues in tomatoes are identified, CRISPR-Cas9 and TILLING mutants are created and analyzed. The results showed that the functions of JKD in root development and resistance to botrytis are conserved. The broad presence of JKD orthologs makes them a great target for molecular breeding to generate crops that do not have to sacrifice their normal growth to defense response.

Background: A major problem in the treatment of human hypertension is the late diagnosis of hypertension and, hence, the delayed start of treatment. Very often, hypertension has existed for a long time and cardiac damage has already developed. Therefore, we tested whether late- onset antihypertensive treatment is effective in lowering blood pressure (BP) and in reducing or even preventing left ventricular hypertrophy and fibrosis. Methods: Twenty-one male 60-week-old spontaneously hypertensive rats (SHR) were included. Fourteen rats received oral treatment with captopril (CAP) either as monotherapy or combined with nifedipine (CAP + NIF) over 22 weeks. Seven untreated SHR served as controls. We examined the therapeutic effects on BP, heart weight and histological and biochemical markers of left ventricular remodeling and fibrosis. Results: At 82 weeks of age, BP was reduced in the CAP and CAP + NIF groups by 44 and 51 mmHg, respectively (p < 0.001), but not in untreated controls. Despite the late therapy start, cardiac hypertrophy and fibrosis were attenuated compared to controls. Both treatments reduced heart weight by 1.2 mg/g (25%, p = 0.001) and collagens I and III by 66% and 60%, respectively (p < 0.001), thus proving nearly equivalent cardioprotective efficacy. Conclusion: These data clearly emphasize the benefit of antihypertensive treatment in reducing BP and mitigating the development of cardiac amage even when treatment is started late in life.

L’hypertrophie du ventricule gauche (HVG) est un processus adaptif et compensatoire qui se développe conséquemment à l’hypertension artérielle pour s’opposer à l’élévation chronique de la pression artérielle. L’HVG est caractérisée par une hypertrophie des cardiomyocytes suite à l’augmentation de la synthèse d’ADN, une prolifération des fibroblastes, une augmentation du dépôt de collagène et une altération de la matrice extracellulaire (MEC). Ces changements génèrent des troubles de relaxation et mènent au dysfonctionnement diastolique, ce qui diminue la performance cardiaque. La suractivité du système nerveux sympathique (SNS) joue un rôle essentiel dans le développement de l’hypertension artérielle et de l’HVG à cause de la libération excessive des catécholamines et de leurs effets sur la sécrétion des cytokines pro-inflammatoires et sur les différentes voies de signalisation hypertrophiques et prolifératives. Le traitement antihypertenseur avec de la moxonidine, un composé sympatholytique d’action centrale, permet une régression de l’HVG suite à une réduction soutenue de la synthèse d'ADN et d’une stimulation transitoire de la fragmentation de l'ADN qui se produit au début du traitement. En raison de l’interaction entre l’HVG, les cytokines inflammatoires, le SNS et leurs effets sur les protéines de signalisation hypertrophiques, l’objectif de cette étude est de détecter dans un modèle animal d’hypertension artérielle et d’HVG, les différentes voies de signalisation associées à la régression de l’HVG et à la performance cardiaque. Des rats spontanément hypertendus (SHR, 12 semaines) ont reçu de la moxonidine à 0, 100 et 400 µg/kg/h, pour une période de 1 et 4 semaines, via des mini-pompes osmotiques implantées d’une façon sous-cutanée. Après 4 semaines de traitement, la performance cardiaque a été mesurée par écho-doppler. Les rats ont ensuite été euthanasiés, le sang a été recueilli pour mesurer les concentrations des cytokines plasmatiques et les cœurs ont été prélevés pour la détermination histologique du dépôt de collagène et de l'expression des protéines de signalisation dans le ventricule gauche. Le traitement de 4 semaines n’a eu aucun effet sur les paramètres systoliques mais a permis d’améliorer les paramètres diastoliques ainsi que la performance cardiaque globale. Par rapport au véhicule, la moxonidine (400 µg/kg/h) a permis d’augmenter transitoirement la concentration plasmatique de l’IL-1β après une semaine et de réduire la masse ventriculaire gauche. De même, on a observé une diminution du dépôt de collagène et des concentrations plasmatiques des cytokines IL-6 et TNF-α, ainsi qu’une diminution de la phosphorylation de p38 et d’Akt dans le ventricule gauche après 1 et 4 semaines de traitement, et cela avec une réduction de la pression artérielle et de la fréquence cardiaque. Fait intéressant, les effets anti-hypertrophiques, anti-fibrotiques et anti-inflammatoires de la moxonidine ont pu être observés avec la dose sous-hypotensive (100 µg/kg/h). Ces résultats suggèrent des effets cardiovasculaires bénéfiques de la moxonidine associés à une amélioration de la performance cardiaque, une régulation de l'inflammation en diminuant les niveaux plasmatiques des cytokines pro-inflammatoires ainsi qu’en inhibant la MAPK p38 et Akt, et nous permettent de suggérer que, outre l'inhibition du SNS, moxonidine peut agir sur des sites périphériques. / Left ventricular hypertrophy (LVH) is an adaptive and compensatory process that develops in hypertension to oppose the chronic elevation of blood pressure. LVH is characterized by hypertrophy of cardiomyocytes following the increase in DNA synthesis, proliferation of fibroblasts, increased collagen deposition and alteration of the extracellular matrix (ECM). These changes generate relaxation and diastolic dysfunction which reduced cardiac performance. The overactivity of the sympathetic nervous system plays an essential role in the development of hypertension and left ventricular hypertrophy pathogenesis due to the excessive release of catecholamines and norepinephrine spillover and their effects on the secretion of pro-inflammatory cytokines and hypertrophic signaling pathways. Antihypertensive treatment with moxonidine, a centrally acting sympatholytic imidazoline compound, results in prevention of left ventricular hypertrophy, resulting from a sustained reduction of DNA synthesis and transient stimulation of DNA fragmentation that occur early after treatment. Due to the interaction between LVH, inflammatory cytokines, the SNS and their effects on hypertrophic signaling proteins, the objective of this study is to detect in an animal model of hypertension and LVH, the different signaling pathways associated with regression of LVH and cardiac performance. Spontaneously hypertensive rats (SHR, 12 weeks old) received moxonidine at 0, 100 and 400 µg/kg/h, for 1 and 4 weeks, via subcutaneously implanted osmotic minipumps. After 4 weeks of treatment, cardiac performance was measured by echo-Doppler. Then the rats were euthanized, blood was collected for measurement of plasma cytokines and hearts for histologic determination of collagen deposition and for measurement of left ventricular expression of downstream signaling proteins. Treatment for 4 weeks had no effect on systolic parameters but improved diastolic parameters and global cardiac performance. Compared to vehicle, moxonidine (400 µg/kg/h) transiently increased plasma IL-1β after 1 week and reduced left ventricular mass. Similarly, there was a decrease in collagen deposition and plasma concentrations of IL-6 and TNF-α, and decreased phosphorylation of p38 and Akt in the left ventricle after 1 and 4 weeks treatment, in association with reduced blood pressure and heart rate. Interestingly, the anti-hypertrophic, anti-fibrotic, and anti-inflammatory effects of moxonidine were observed with a sub-hypotensive dose (100µg/kg/h). These results suggest the beneficial cardiovascular effects of moxonidine associated with improved cardiac performance, regulation of inflammation by decreasing pro-inflammatory plasma levels, inhibition of p38 MAPK and Akt, and allow us to suggest that besides inhibiting the SNS, moxonidine may act on peripheral sites.

Para avaliar as repercussões da insuflação prolongada da cavidade peritoneal com gás carbônico sobre a hipertensão arterial essencial, utilizou-se ratos machos espontaneamente hipertensos (SHR) e como normotensos ratos machos Wistar-Kioto (WKY). No total foram utilizados 34 animais, sendo 22 SHRs e 12 WKYs, onde os ratos SHR foram distribuídos aleatoriamente aos grupos G1 e G3. O primeiro grupo (G1) com 12 animais SHRs e o segundo (G2) com 12 animais WKYs foram expostos a pneumoperitônio com dióxido de carbono por 120 minutos, enquanto que o terceiro grupo (G3) com 10 animais SHRs, passou por insuflação da cavidade peritoneal, seguida de punção com trocarte e esvaziamento do pneumoperitônio. Os animais deste grupo permaneceram anestesiados e com o abdome puncionado por 2 horas. Previamente a confecção do pneumoperitônio, a artéria e veia femorais direita foram dissecadas e canuladas. A artéria foi conectada ao transdutor de pressão para o registro contínuo da pressão arterial (PA), após a coleta inicial de 0,2 ml para dosagem da gasometria basal e 0,8 ml para as dosagens de uréia (U) e creatinina (Cr) basais. A veia femoral foi uttilizada para a expansão volêmica lenta com 10 ml de solução fisiológica após a coleta inicial de 1,0 ml de sangue arterial. Feito isto, procedeu-se a insuflação e punção abdominal mantendo ou não o pnemoperitônio, conforme o grupo. Foram feitas medidas da pressão arterial a cada 15 minutos e 5 minutos após o esvaziamento do abdome. Após a última aferição, foi colhido aproximandamente 3 ml de sangue arterial e 1 ml para a gasometria mais dosagem da U e Cr. A análise multivariada para medidas repetidas ao longo do tempo permitiu concluir que: nos cinco minutos após a desinsuflação, houve diferença estatística significante (p<0,0001) nas pressões arteriais sistólica, diastólica e média no G1 com uma curva ascendente em relação ao G2 e G3; O pH diminuiu (p<0,0001) de maneira similar nos três grupos de intervenção, enquanto a pCO2 aumentou (p<0,0001) de maneira similar nos três grupos de intervenção; não houve mudanças significativas na creatinina (p=0,3232); a uréia apresentou um efeito de momento com significância estatística (p<0,0001) e a atividade da renina plasmática foi significativamente maior no G2 em relação aos outros dois grupos / To assess the effects of prolonged peritoneal cavity insufflation with carbon dioxide on the essential hypertension, a experimental study was designed using male spontaneously hypertensive rats (SHR) and male normotensive Wistar-Kyoto (WKY). Thirty-four animals were used, 22 SHRs and 12 WKYs, where SHR rats were randomly assigned to groups G1 and G3. The first group (G1) with 12 animals SHRs and second group (G2) with 12 animals WKYs were exposed to pneumoperitoneum with carbon dioxide for 120 minutes, while the third group (G3) with 10 animals SHRs, had the peritoneal cavity insufflated, followed by puncture with trocarte and released the pneumoperitoneum. The animals of this group remained anesthetized and the abdomen punctured by 2 hours. Before making the pneumoperitoneum, right femoral artery and vein were dissected and cannulated. The artery was connected to the transducer pressure for the continuous recording of blood pressure (BP), after the initials blood samples: 0.2 ml for blood gases measurement and 0.8 ml for urea (U) and creatinine (Cr ). The femoral vein was used to volume expansion with 10 ml of saline solution after the initial sample of 1.0 ml arterial blood. Afterwards, a pnemoperitoneum insufflation and maintaining is done or not, depending on group. Blood pressure was recorded every 15 minutes and 5 minutes after pnemoperitoneum released. After last blood pressure record, a 3.0 ml blood sample was collected to measure plasma renin activity (PRA), and 1.0 ml for blood gases measurement, urea (U) and creatinine (Cr). The multivariate analysis for repeated measurements over time has concluded that: five minutes after pnemoperitoneum released, systolic, diastolic and mean blood pressure has significant statistic differences (p <0.0001) in G1 with an upward curve in relation to G2 and G3; The pH decreased (p <0.0001) in a similar way in the three groups of intervention, while pCO2 increased (p <0.0001) in a similar way in the three groups of intervention, with no significant changes in creatinine (p = 0.3232), but the urea had a moment effect with statistical significance (p <0.0001) and the plasma renin activity (PRA) was significantly higher in G2 compared with the other two groups

O emprego de \"Total Genome Scan\" em modelos genéticos de doenças complexas tem sido fundamental para seleção de regiões cromossômicas envolvidas com traços complexos. Em nosso laboratório, identificamos cinco regiões cromossômicas associadas ao traço quantitativo pressão arterial (BP-QTL) que explicam 43% da variação da pressão arterial numa progênie obtida a partir de animais espontaneamente hipertensos (SHR) e \"Brown Norway\" (BN). Os BP-QTLs foram, então, validados por desenvolvimento de linhagens congênicas, incluindo uma para o cromossomo 4 (SHR.BN4) cuja substituição das sequências SHR pelo do animal BN levou a redução da pressão arterial sistólica basal (~14 mm Hg). O objetivo deste trabalho foi identificar as variantes genéticas candidatas neste intervalo cromossômico com base em diferenças no padrão de expressão gênica e na presença de alterações genéticas não sinônimas \"missense\" ou em regiões regulatórias conservadas que possam estar envolvidas na gênese da hipertensão. Identificamos 533 genes com expressão renal, dentre os 682 do intervalo, sendo que 28 apresentaram padrão de expressão diferente entre amostras de animais adultos (congênico vs. SHR) e seis apresentaram alterações não sinônimas \"missense\". É importante salientar que dos genes diferentemente expressos, encontramos alterações estruturais em regiões conservadas com potencial de participar na regulação em 11. Em conjunto, utilizamos uma plataforma integrada para selecionar 34 genes candidatos no cromossomo 4, dos quais 17 genes serão priorizados, para ser investigados quanto sua contribuição na hipertensão arterial do SHR e na hipertensão primária humana / Total genome scan in genetic models of complex diseases have been instrumental to select candidate genes underlying complex traits. We previously mapped 5 blood pressure related quantitative trait loci (BP-QTLs) that explain about 43% of the BP variance in a progeny derived from Spontaneous Hypertensive Rat (SHR) and Brown Norway (BN) rats. The BP-QTLs were then validated by derivation of congenic strains, including one for chromosome 4 (SHR.BN4) in which a segment from BN replaced the SHR sequences reducing basal systolic BP (~14 mm Hg). The aim of this project is to identify the candidate genetic variants within the chromosome interval based on differences in renal gene expression patterns and structural changes in both non-synonymous missense or within adjacent regulatory sequences that may contribute to hypertension. We identified 533 genes with renal expression, out of 682 in the interval, in which 28 presented differences in expression pattern in adult samples (congenic vs. SHR) and six presented non-synonymous missense alterations. In addition, 11 out of 28 differentially expressed genes showed structural alterations in adjacent conserved regions that potentially contribute to gene regulation. Taken together, using the proposed combination of strategies, we selected 34 hypertensive candidate genes in chromosome 4, in which 17 will be prioritized, to be further explored to assess their contribution to hypertension in the SHR and to essential hypertension in humans